BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37903180)

  • 1. Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.
    Herbst RS; Blanke CD; Sigal EV
    Clin Cancer Res; 2024 Jan; 30(1):29-32. PubMed ID: 37903180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW; Papadimitrakopoulou VA; Minichiello K; Hirsch FR; Mack PC; Schwartz LH; Vokes E; Ramalingam S; Leighl N; Bradley J; Miao J; Moon J; Highleyman L; Miwa C; LeBlanc ML; Malik S; Miller VA; Sigal EV; Adam S; Wholley D; Sigman C; Smolich B; Blanke CD; Kelly K; Gandara DR; Herbst RS
    Lancet Oncol; 2020 Dec; 21(12):1589-1601. PubMed ID: 33125909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
    Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
    PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic and therapeutic study of novel anti-tumor function of natural compound imperialine for treating non-small cell lung cancer.
    Lin Q; Qu M; Patra HK; He S; Wang L; Hu X; Xiao L; Fu Y; Gong T; He Q; Zhang L; Sun X; Zhang Z
    J Ethnopharmacol; 2020 Jan; 247():112283. PubMed ID: 31605736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Best practice in the treatment of advanced squamous cell lung cancer.
    Ang YL; Tan HL; Soo RA
    Ther Adv Respir Dis; 2015 Oct; 9(5):224-35. PubMed ID: 25902866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers.
    Genova C; Rijavec E; Grossi F
    Expert Rev Anticancer Ther; 2016; 16(1):1-4. PubMed ID: 26567561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-surgical therapy for patients with advanced non-small cell lung cancer.
    Liao M
    Respirology; 1998 Sep; 3(3):151-7. PubMed ID: 9767613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
    Castillo DR; Jeon WJ; Park D; Pham B; Yang C; Joung B; Moon JH; Lee J; Chong EG; Park K; Reeves ME; Duerksen-Hughes P; Mirshahidi HR; Mirshahidi S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
    Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced
    Solassol I; Pinguet F; Quantin X
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31671561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma.
    Kuribayashi K; Funaguchi N; Nakano T
    J Cancer Res Ther; 2016; 12(2):528-34. PubMed ID: 27461605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
    Chen HL; Shen LJ; Wei CP; Lu HM; Hsiao FY
    J Eval Clin Pract; 2015 Oct; 21(5):808-16. PubMed ID: 26096761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Event Management in Patients with
    Chalmers A; Cannon L; Akerley W
    Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Cell Composition in Human Non-small Cell Lung Cancer.
    Stankovic B; Bjørhovde HAK; Skarshaug R; Aamodt H; Frafjord A; Müller E; Hammarström C; Beraki K; Bækkevold ES; Woldbæk PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
    Front Immunol; 2018; 9():3101. PubMed ID: 30774636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
    Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
    Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.